|
|
01 Mar 2010
The chief financial officer of Silence Therapeutics has resigned.
Melvyn Davies, who was also company secretary, had been with Silence for 15 years. He will assist the company for up to three months until they find a successor.
Silence, which specialises in treating serious diseases with biotechnology, also announced the resignation of Iain Ross, chairman and a director of the board. The board has appointed Jerry Randall, senior independent director, to replace him.
Randall said: "I would like to extend my own and the board’s heartfelt thanks to both Iain and Melvyn for all they have contributed to Silence.”
Further reading:
Female accountants paid 60% less than men
You may also like
Search thousands of financial jobs:
Search thousands of financial jobs:
Careers
Search for jobs
Click to search our database of all the latest accountancy roles
Create a profile
Click to set up your profile and let the best recruiters find you
Jobs by email
Sign up to receive regular updates with the latest roles suitable for you
Briefings
By looking at the reasons supplier statements became unfashionable, and the reasons why it is different today, this paper delves into the many benefits that can be obtained by automating the process.
Having a real and true view of your organisation’s current financial position, and having the right systems and processes in place, will ensure that you can make strong choices and are ready to capitalise on opportunities
AccountancyAgeInsight is a frequently updated resource centre for finance professionals, offering a free and easy-to-use digital library of briefings, white papers and other information resources. 
Visitor comments Add your comment